MGTX

MeiraGTx Holdings plc

13.88 USD

Last updated Sep 4, 21:02 UTC

Yesterday HIGH

$14.15

Yesterday LOW

$13.76

52w HIGH

$15.35

52w LOW

$6.62

EPS

1.71

PE

8.12

Next Earnings

Nov 12, 2026

Overview News Insider Transactions Government Trades Fundamentals

MeiraGTx Holdings plc stock is up 10.6% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 77.78% of the previous 8 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Insights

Thu Apr 16, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session
Vandana Singh

Thu Apr 16, 2026

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.
Benzinga Newsdesk

Thu Apr 16, 2026

MeiraGTx Holdings shares are trading lower after the company announced the pricing of its $100 million offering of 11,111,111 shares at $9 per share. Also, the company entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in bota-vec for the treatment of XLRP.
Benzinga Insights

Thu Apr 16, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Newsdesk

Thu Apr 16, 2026

MeiraGTx Holdings Prices Underwritten Offering Of 11,111,111 Of Its Ordinary Shares At $9/Shr; Gross Proceeds Expected To Be ~$100M

MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price ofMeiraGTx Holdings plc (NASDAQ:MGTX), a vertica
Benzinga Newsdesk

Thu Apr 16, 2026

MeiraGTx Enters Into Asset Purchase Agreement With Johnson & Johnson To Buy All Interests In Bota-Vec For Treatment Of XLRP; MeiraGTx To Pay J&J $25M Upfront, Milestone Fees, High Double‑Digit Royalties On Bota‑Vec Sales

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa
Benzinga Newsdesk

Thu Apr 16, 2026

MeiraGTx's Three-Year Data From Completed Phase 1 AQUAx Study Of AAV-hAQP1 For Grade 2/3 Late Radiation-Induced Xerostomia Shows Meaningful Improvements In Symptoms

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts.Increases in
Benzinga Newsdesk

Tue Apr 14, 2026

MeiraGTx Holdings shares are trading higher after the company announced it will present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia.
Benzinga Newsdesk

Tue Apr 14, 2026

MeiraGTx Holdings To Present 3-Year Data From Participants In Phase 1 Trial Of AAV-hAQP1 To Treat Persistent Grade 2/3 Moderate To Severe Radiation-Induced Xerostomia

MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of
Benzinga Newsdesk

Wed Apr 1, 2026

Evercore ISI Group Maintains Outperform on MeiraGTx Hldgs, Lowers Price Target to $18

Evercore ISI Group analyst Gavin Clark-Gartner maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and lowers the price target from $20 to $18.

RBC Capital

Fri Aug 14, 17:27

buy

confirm

Advanced Data Unlock

Alexandria Forbes, PRESIDENT & CEO

Tue Aug 18, 2026

MGTX Recent Insider Trades and Stock Chart

62,000 shares sold

Advanced Data Unlock

ALAB $310.56 USD

AZN $162.67 USD

BETR BETR $14.46 USD

AAPL $319.87 USD

LULU $100.57 USD

NVTS $11.81 USD

IREN $44.64 USD

NFLX $78.29 USD

MU $1,015.36 USD